Feed AXSM
AX

Axsome Therapeutics

AXSM · NASDAQ

$204.07 -5.09% (-$10.95)
1M -5.64%
Market Cap $11.1B
P/E Ratio -
Div. Yield -
ROE 255.60%

Bulios Fair Price

$180.33

11.6% downside

Current Price

$204.07

Undervalued Fair Value Overvalued

According to Bulios Fair Price, AXSM is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/B 133.79x
P/S 14.35x
EV/EBITDA N/A
Growth
78 /100
Growing
Book val. growth 6.94%
Rev. growth 133.68%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 24.68%
Op. margin 24.28%
FCF margin 9.19%
Quality
13 /100
Poor
ROE 255.60%
ROA 25.17%
Asset turnover 1.02x
Debt
16 /100
High
Current ratio 1.43x
Int. coverage -37.09x
Debt/Equity 2.63x
Stability
45 /100
Moderate
Rev. volatility 223.59%
EPS volatility 30.42%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AXSM
Online

About the company

Axsome Therapeutics, Inc. (AXSM) is a biotechnology company focused on the development and commercialization of innovative drugs for the treatment of various neurologic and psychiatric disorders. The company targets therapeutic areas such as depression, migraines, Alzheimer's disease, and other neurological conditions that have a significant impact on human health. Axsome Therapeutics aims to improve the quality of life for patients by offering novel and effective treatment options. With active research and clinical trials, the company has a promising pipeline of drugs that can have a positive impact on healthcare and the medical industry. Investing in Axsome Therapeutics, Inc. (AXSM) shares can be an attractive choice for investors who follow the biotechnology and pharmaceutical sectors and seek a company with the potential for significant growth and innovative treatment approaches.

Sector

Healthcare

Industry

Biotechnology

CEO

Herriot Tabuteau

Employees

1,346

Headquarters

New York City

Upcoming events

02 NOV

Earnings

Upcoming earnings report

47d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.